Launch Date
07/28/2023 at 4:00 am EST
Credit Amount
0.25
Credit Expires
07/28/2024
Patients with narcolepsy are at a higher risk for CV and cardiometabolic dysfunction, hypertension (HTN) being a key player in development of these dysfunctions. In two recent studies, patients with narcolepsy were found to have a 1.32 times increased risk of HTN, 2.5 times increased risk of stroke, 1.6 times increased risk of myocardial infarction (MI), 1.6 times increased risk of cardiac arrest, 2.6 times increased risk of heart failure (HF), 2.2 times increased risk of coronary atherosclerosis, and 2.07 times increased risk of heart disease. In order to manage these dangerous comorbidities clinicians must utilize pharmacotherapies that offer reduced sodium intake while closely managing dosing and titration.
In this CMEO Snack, entitled Managing Cardiovascular Risk in Patients with Narcolepsy, expert faculty will discuss strategies for initiating and switching treatment plans for patients with narcolepsy that consider comorbidities, dosing, and titration strategies.
Initiate, or where appropriate, switch treatment plans for narcolepsy that consider cardiovascular comorbidities, dosing, and titration strategies.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Sleep specialists, primary care physicians, pulmonologists, neurologists, psychiatrists, physician associates (PAs), nurse practitioners (NPs), nurses, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Bogan reports the following financial relationships:
Consultant: Avadel; Axsome Therapeutics, Inc.; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; Oventus; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Apnimed; Avadel; Bayer; Bresotec Medical; Eisai Inc.; Fisher Paykel Healthcare; FRESCA Medical; Idorsia Pharmaceuticals US Inc.; Jazz Pharmaceuticals, Inc.; LivaNova; Merck & Co., Inc.; NLS Pharmaceutics; Philips; Roche; Sanofi; Sommetrics, Inc.; Suven Pharma; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals Inc.
Speakers Bureau: Eisai Inc.; Harmony Biosciences; Idorsia Pharmaceuticals US Inc.; and Jazz Pharmaceuticals, Inc.
Dr. Morse reports the following financial relationships:
Advisory Board: Alkermes; Avadel; Harmony Biosciences; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Grants: Coverys Community Healthcare Foundation; Jazz Pharmaceuticals, Inc.; and ResMed Foundation
Research Support: Geisinger Health Plan; Jazz Pharmaceuticals, Inc.; and UCB, Inc.
Speakers Bureau: Jazz Pharmaceuticals, Inc.
Employment: DAMM Good Sleep, LLC (CEO)
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
SN-212-072823-43